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Although many proteins have been shown to participate
in ligand-stimulated endocytosis of EGF receptor (EGFR),
the adaptor protein responsible for interaction of acti-
vated EGFR with endocytic machinery remains elusive.
We show here that EGF stimulates transient tyrosine
phosphorylation of Tom1L1 by the Src family kinases,
resulting in transient interaction of Tom1L1 with the
activated EGFR bridged by Grb2 and Shc. Cytosolic
Tom1L1 is recruited onto the plasma membrane and
subsequently redistributes into the early endosome.
Mutant forms of Tom1L1 defective in Tyr-phosphorylation
or interaction with Grb2 are incapable of interaction
with EGFR. These mutants behave as dominant-negative
mutants to inhibit endocytosis of EGFR. RNAi-mediated
knockdown of Tom1L1 inhibits endocytosis of EGFR.
The C-terminal tail of Tom1L1 contains a novel clathrin-
interacting motif responsible for interaction with the
C-terminal region of clathrin heavy chain, which is
important for exogenous Tom1L1 to rescue endocytosis
of EGFR in Tom1L1 knocked-down cells. These results
suggest that EGF triggers a transient Grb2/Shc-mediated
association of EGFR with Tyr-phosphorylated Tom1L1 to
engage the endocytic machinery for endocytosis of the
ligand–receptor complex.
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Introduction
Endocytosis of surface proteins occurs either constitutively
(e.g. the transferrin receptor, TfR) or only on ligand binding
(e.g. the EGF receptor, EGFR). Clathrin mediates endocytosis
of many surface proteins (Kirchhausen, 2000; Le Roy and
Wrana, 2005; Roth, 2006), which is generally facilitated by
adaptor proteins that bind simultaneously to cargo proteins
and clathrin. Many accessory proteins also participate in
endocytosis (Slepnev and De Camilli, 2000; Traub, 2003).
AP-2, b-arrestin, autosomal recessive hypercholesterolemia
(ARH) and disabled-2 (Dab2) are examples of known adap-
tors mediating endocytosis of various surface proteins. AP-2,
a heterotetrameric protein complex consisting of small s2,
medium m2, and large a and b2 subunits, is involved in
endocytosis of many surface proteins such as TfR through
binding to double leucine or Tyr-based endocytic motifs in
the cytoplasmic domain of the surface proteins (Bonifacino
and Lippincott-Schwartz, 2003; Traub, 2003; Robinson,
2004). b-arrestins are specialized adaptors responsible for
endocytosis of G-protein coupled receptors such as b2-adre-
nergic receptor (Lefkowitz and Shenoy, 2005; Moore et al,
2007; Wolfe and Trejo, 2007). ARH and Dab2 are speciﬁc
adaptors responsible for endocytosis of the LDL receptor
(Keyel et al, 2006; Maurer and Cooper, 2006).
EGFR is an example of a family of surface proteins termed
as receptor tyrosine kinases (RTKs) (Blume-Jensen and
Hunter, 2001; Schlessinger, 2004; Citri and Yarden, 2006).
Ligand binding generally causes dimerization of the receptor
and consequent activation of the tyrosine kinase activity of
the intracellular cytoplasmic domain to mediate intracellular
signalling. Ligand binding also induces endocytosis of the
activated receptor. Overexpression of EGFR or its defective
endocytosis because of mutations is causally linked to several
human cancers (Peschard and Park, 2003; Citri and Yarden,
2006; Lo et al, 2006; Sharma et al, 2007). Endocytosis of
EGFR is mediated by clathrin, but several studies have
suggested that AP-2 does not have a major function in
EGF-stimulated clathrin-dependent endocytosis of EGFR
(Nesterov et al, 1999; Conner and Schmid, 2003; Motley
et al, 2003; Traub, 2003; Lakadamyali et al, 2006; Sorkin
and Goh, 2009), suggesting the existence of additional or
alternative adaptors responsible for endocytosis of EGFR.
Identiﬁcation of such adaptors will greatly enhance our
understanding of the emerging function of endocytosis in
cellular signalling and endocytic sorting (Traub, 2003; Le Roy
and Wrana, 2005; Citri and Yarden, 2006; Deinhardt et al,
2006; Lakadamyali et al, 2006; Polo and Di Fiore, 2006).
Tom1L1 belongs to the VHS domain-containing family of
proteins, which also include Hrs, Stam1, Stam2, GGA1,
GGA2, GGA3, Tom1 and Tom1L2 (Lohi et al, 2002;
Bonifacino, 2004). Characterized by an N-terminal VHS
domain followed by a central GAT domain and a C-terminal
region, Tom1, Tom1L1 and Tom1L2 together form a subfam-
ily of VHS domain proteins. Tom1 is known to be recruited to
the endosome by endoﬁn (an endosomal FYVE domain
protein) and can subsequently recruit clathrin onto the
endosome (Seet et al, 2004; Seet and Hong, 2005). Tom1L1
is Tyr-phosphorylated by the Src family kinases and may have
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3485a negative function in Src kinase signalling (Seykora et al,
2002; Franco et al, 2006). Furthermore, Tom1L1 can interact
with Hrs and TSG101/VPS23, which are important for sorting
of endocytosed EGFR into multivesicular bodies (MVBs) for
delivery to the lysosome for degradation (Puertollano, 2005).
In this report, we provide evidence showing that Tom1L1 is a
regulated adaptor bridging activated EGFR with the endocytic
machinery for internalization of activated EGFR.
Results
Src family kinases, stimulated by EGF, catalyse
Y460-dependent tyrosine phosphorylation of
Tom1L1 to mediate interaction with Grb2
Mouse Tom1L1 is phosphorylated by the Src kinase family
(Seykora et al, 2002). Human Tom1L1, but not its related
Tom1 or Tom1L2, is also tyrosine phosphorylated by Src
(Supplementary Figure S1A and B). Several mutants of
Tom1L1 were created to deﬁne the residue responsible for
its Tyr-phosphorylation, including Tom1L1–SH3 in which the
potential SH3 domain-binding motif (
421LPPLP) was mutated
into AAAAA, Tom1L1/Y392F in which Y392 was mutated to F
to disrupt the potential Grb2-binding motif, Tom1L1/Y460F
in which Y460 was mutated to F to disrupt the potential Src-
phosphorylation motif and Tom1L1/Y460F–SH3 in which
both the SH3-interacting motif and Src target motif were
mutated (Figure 1A). Examining these mutants revealed
that Y460 is necessary for phosphorylation (Supplementary
Figure S1C). The Src-related Fyn kinase also phosphorylated
Tom1L1, but not Tom1 or Tom1L2 (Supplementary Figure
1D). In view of the interaction of Tom1L1 with Grb2 (Seykora
et al, 2002) and the potential function of Grb2 in endocytosis
of EGFR (Johannessen et al, 2006), we found that Tyr-
phosphorylation of Tom1L1 is important for interaction
with Grb2, as Tom1L1 failed to interact with Grb2 in the
absence of the kinase (Supplementary Figure S1E).
Consistently, Y460F also disrupted the interaction with Grb2
(Supplementary Figure S1F). Although EGF-stimulated Tyr-
phosphorylation was not affected by Y392F mutation
(Supplementary Figure S1G), Y392F mutation also abolished
the interaction with Grb2 (Supplementary Figure 1F). These
results suggest that Src-catalysed Tyr-phosphorylation at
Y460 of Tom1L1 triggers interaction with Grb2 that is also
dependent on Y392. These two residues may thus act in a
concerted manner for Tom1L1 to interact with Grb2. Tom1L1
is also Tyr-phosphorylated under physiological stimulations.
A431 cells stably expressing HA–Tom1, Tom1L1 or Tom1L2
were treated with EGF for 5min followed by immunopreci-
pitation and immunoblot. HA-tagged proteins were efﬁciently
precipitated regardless of EGF stimulation (Figure 1B, lower
panel). Probing with phospho-Tyr, 4G10 Mab showed that
Tom1L1 was Tyr-phosphorylated, and this was observed only
after EGF stimulation (Figure 1B, upper panel). Mutation of
Y460 abolished EGF-stimulated Tyr-phosphorylation of
Tom1L1 (Figure 1C). To examine whether Tom1L1 is Tyr-
phosphorylated on stimulation by other ligands of RTKs, we
treated NIH-3T3 cells expressing HA–Tom1L1 and its mutants
with PDGF-BB (Figure 1D) or FGF2 (Figure 1E). Both PDGF-
BB and FGF2 stimulated Y460-dependent Tyr-phosphoryla-
tion of Tom1L1. As Y460 is Tyr-phosphorylated by Src family
kinases, we tested the possibility that Tyr-phosphorylation of
Tom1L1, stimulated by EGF, PDGF-BB and FGF2, may be
mediated by Src family kinases. In support of this possibility,
EGF-stimulated Tyr-phosphorylation of Tom1L1 was essen-
tially abolished in the presence of Src kinases inhibitor PP1
(Figure 1F). Furthermore, in SYF mouse cells lacking Src, Yes
and Fyn, EGF, PDGF-BB or FGF2 failed to stimulate
Tyr-phosphorylation of Tom1L1, in contrast to their ability
to stimulate Tyr-phosphorylation of Tom1L1 in NIH-3T3
mouse cells (Figure 1G). These results suggest that EGF,
PDGF and FGF stimulate Tyr-phosphorylation of Tom1L1
through Src family kinases, which are known to be activated
by these ligands (Martin, 2001; Ishizawar and Parsons, 2004).
EGF-stimulated Tyr-phosphorylation of Tom1L1
is transient and correlates with its transient
interaction with EGFR
We next examined the kinetics of EGF-stimulated Tyr-phos-
phorylation of Tom1L1. A431 cells expressing HA–Tom1L1
were stimulated with EGF for various periods of time. Cell
lysates were precipitated with anti-HA antibody followed by
immunoblot (Figure 2A, upper two panels). When probed
with 4G10 Mab, Tom1L1 was observed to be Tyr-phosphory-
lated after stimulation for 2min, with the maximal level of
Tyr-phosphorylation being detected at 5min. At 10min, Tyr-
phsophorylated Tom1L1 was signiﬁcantly reduced. At 20min
and beyond, Tom1L1 was no longer phosphorylated. In
addition to Tyr-phosphorylated Tom1L1, another Tyr-phos-
phorylated protein of about 180–200kDa was detected by
4G10 Mab (Figure 2A, upper band of upper panel). As EGFR
is about 180–200kDa and is Tyr-phosphorylated on EGF
stimulation (Supplementary Figure S2) (Zhang et al, 2005;
Olsen et al, 2006), we probed the same blot with antibodies
against EGFR and a similar pattern was observed (Figure 2A,
second panel). These results suggest that EGF not only
stimulated Tyr-phosphorylation of Tom1L1, but also triggered
a transient association of Tyr-phosphorylated Tom1L1 with
Tyr-phosphorylated EGFR. As co-immunoprecipitation of
EGFR was not detected for Tom1L1/Y460F or Tom1L1/
Y392F (Figure 2B), Tyr-phosphorylation mediated by Src
family kinases and its ability to interact with Grb2 are both
important for Tom1L1 to interact with activated EGFR.
To study endogenous Tom1L1, we raised two speciﬁc anti-
bodies against Tom1L1. The ﬁrst antibody (anti-Tom1L1) was
raised against recombinant C-terminal tail (residues 286–476)
of Tom1L1 and it recognized both endogenous Tom1L1 and
HA-tagged Tom1L1, but did not react with Tom1 or Tom1L2
(Supplementary Figure S3A and B). Another antibody
(anti-pTom1L1) was raised using a short peptide
(
456TEAIpYEEIDAHQHKG
470) in which Y460 is phosphory-
lated. Although the anti-pTom1L1 antibody recognized both
Tyr-phosphorylated Tom1L1 and Tom1L1 (Supplementary
Figure S3C), it has a higher afﬁnity for Tyr-phosphorylated
Tom1L1. When the antibody was tested in starved cells (in
which no Tyr-phosphoryated Tom1L1 was present) or cells
stimulated with EGF, the anti-pTom1L1 signal was decreased
or increased, respectively (Supplementary Figure S3D, sec-
ond panel), indicating that this antibody has a higher afﬁnity
for Tyr-phosphorylated Tom1L1 than unphosphorylated
Tom1L1 (Supplementary Figure S3D, ﬁrst panel, lane 2).
We have used these antibodies to study the behaviour of
endogenous Tom1L1. On stimulation with EGF, endogenous
Tom1L1 (Figure 2C, lower band of upper panel) was Tyr-
phosphorylated with similar kinetics as HA-tagged Tom1L1.
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band of upper panel and middle panel) was also transiently
co-immunoprecipitated with Tom1L1 by anti-Tom1L1 anti-
body with kinetics correlating with the pattern of Tom1L1
Tyr-phosphorylation. The signals detected with anti-pTom1L1
antibody were also transiently increased during EGF stimula-
tion (Figure 2C, third panel), conﬁrming that it has a higher
afﬁnity for Tyr-phosphorylated Tom1L1. EGF stimulation
thus induces transient Tyr-phosphorylation of endogenous
Tom1L1 and interaction with Tyr-phosphorylated EGFR.
An earlier study has shown that Grb2 can interact with EGFR
indirectly through Shc (Rozakis-Adcock et al, 1992; Vieira
et al, 1996), enabling the SH2 domain of Grb2 to interact with
other proteins. Shc may thus mediate interaction of Tom1L1–
Grb2 complex with EGFR. The importance of Grb2 and Shc in
mediating the interaction of endogenous Tom1L1 with EGFR
was supported by the observation that EGF-induced co-
immunoprecipitation of EGFR with Tom1L1 was signiﬁcantly
compromised in cells transfected with siRNA to knock down
the expression of Grb2 (Figure 2D, lane 4) or Shc (Figure 2D,
lane 5). Simultaneous knockdown of both Grb2 and Shc led
to robust inhibition of Tom1L1–EGFR interaction (Figure 2D,
lane 6), as compared with cells transfected with non-targeting
siRNA (Figure 2D, lane 3). Furthermore, when 13A9 Mab,
392YDNF395 421LPPLP425 460YEEID464
1VHS154 155GAT285
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Figure 1 EGF, PDGF and FGF stimulate Src-catalysed Tyr-phosphorylation of Tom1L1. (A) Structural features of Tom1L1. The domains and
motifs are indicated. (B) Starved A431 cells expressing the indicated proteins were untreated or treated with EGF (100ng/ml for 5min) as
indicated. Anti-HA precipitates were analysed by immunoblot using the indicated antibody. (C–E) Cells expressing HA–Tom1L1 (wt) or its
various mutants were either untreated or treated with EGF (100ng/ml for 5min) (C), PDGF-BB (50ng/ml for 5min) (D) or FGF2 (20ng/ml for
5min) (E). Anti-HA precipitates were analysed by immunoblot using the indicated antibody. (F) Cells expressing HA–Tom1L1 were either
untreated or treated with EGF in the presence or absence of Src kinase inhibitor PP1 (10nM). Anti-HA precipitates were analysed by
immunoblot as indicated. (G) Mouse NIH-3T3 cells or SYF cells (defective in Src family kinases Src, Yes and Fyn) were either untransfected or
transfected to express HA–Tom1L1. Cells were either untreated or treated with EGF, PDGF-BB or FGF2 as indicated. Anti-HA precipitates were
analysed by immunoblot as indicated.
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interfere with EGF binding to EGFR and signalling
(Sigismund et al, 2005), was ﬁrst incubated with intact
A431 cells followed by EGF stimulation for 0–30min, endo-
genous Tom1L1 was co-recovered with 13A9–EGFR complex
(Figure 2E, lanes 2–4) during the 2–10min interval after EGF
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Figure 2 EGF stimulates transient association of Tyr-phosphorylated Tom1L1 with activated EGFR through Grb2/Shc. (A) Cells expressing
HA–Tom1L1 were treated with 100ng/ml of EGF for the indicated period of time. The cell lysates (lower two panels) and anti-HA precipitates
(upper two panels) were analysed by immunoblot using the indicated antibody. (B) Cells expressing indicated proteins were treated with EGF
(100ng/ml for 5min). Anti-HA precipitates were analysed by immunoblot as indicated. (C) A431 cells were treated with EGF (100ng/ml) for
the indicated period of time. Anti-Tom1L1 precipitates were analysed by immunoblot using the indicated antibody. Cell lysates were also
analysed (bottom two panels). (D) Control A431 cells (lanes 1–2) or cells transfected with control non-targeting siRNA (lane 3) or siRNA-
targeting Grb2 (lane 4), Shc (lane 5) or both (lane 6) were either untreated (lane 1) or treated with EGF (100ng/ml for 5min) (lanes, 2–6). Anti-
Tom1L1 precipitates were analysed to detect the co-immunoprecipitated EGFR (the upper panel) and Tom1L1 (the second panel). The cell
lysates were also analysed using the indicated antibody (bottom three panels). (E) Starved A431 cells were incubated with the 13A9 antibody
(20mg/ml) for 1h at 01C. After washing, the cells were either untreated (lane 1) or treated (lanes 2–6) with EGF (100ng/ml) for the indicated
period of time. The 13A9–EGFR complex was recovered from cell lysates and analysed by immunoblot using the indicated antibody (ﬁrst three
panels). Cell lysates (bottom two panels) were also analysed. (F) A431 cells expressing HA–Tom1L1 were treated with indicated dose of EGF
(0–100ng/ml) for 5min. Anti-EGFR precipitates were analysed by immunoblot using anti-phospho-Tyr antibody (upper panel) and anti-
Tom1L1 antibody (second panel). Anti-Tom1L1 precipitates were also analysed using anti-phospho-Tyr antibody (third panel). The cell lysates
were also analysed using the indicated antibody.
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cells interacts with endogenous Tom1L1 during 2–10min of
EGF stimulation. To gain insight into the dose-dependent
effect, A431 cells stably expressing HA–Tom1L1 were treated
with increasing dose of EGF (0–100ng/ml) for 5min. Tom1L1
(Figure 2F, second panel) was recovered with Tyr-phosphory-
lated EGFR by co-immunoprecipitation with anti-EGFR anti-
body, which is correlated with the pattern of EGFR
Tyr-phosphorylation. Similar result was observed by immu-
noprecipitation using anti-Tom1L1 antibody followed by
probing with 4G10 Mab (Figure 2F, third panel). The activa-
tion of Akt1 exhibited a similar dose-dependent pattern
(Figure 2F, panel 4). These results suggest that 15–20ng/ml
of EGF can achieve optimal response that is comparable to
that elicited by 100ng/ml of EGF with regards to Tyr-phos-
phorylation of EGFR, Tyr-phosphorylation of Tom1L1,
interaction of Tom1L1 with EGFR and activation of Akt1 in
A431 cells. At lower doses (1–10ng/ml) of EGF, EGFR is only
partially tyrosine phosphorylated and not fully competent for
stimulating Tyr-phosphorylation of Tom1L1, inducing inter-
action with Tom1L1, or downstream signalling leading to
Akt1 activation (Figure 2F).
EGF induces recruitment of Tom1L1 from the cytoplasm
to the plasma membrane and subsequent redistribution
with EGFR into the early endosome
Endogenous Tom1L1 is primarily present in the cytoplasm
(Supplementary Figure S4A–C). We then examined the effect
of EGF stimulation on the distribution of endogenous
Tom1L1. Starved A431 cells were treated with EGF for various
periods of time and then processed for immunoﬂuorescence
microscopy using anti-pTom1L1 antibody. Tom1L1 was initi-
ally detected in the cytoplasm, but was observed to be
enriched on the plasma membrane after a 2–5min treatment
with EGF (Figure 3A) and co-localized noticeably with EGFR
and clathrin in A431 cells (Figure 3B). This result was also
conﬁrmed in Hela cells (Supplementary Figure S4D). The
shift in localization corresponded well with the time of
induction of Tyr-phosphorylated Tom1L1 and its interaction
with EGFR. After 10min of EGF treatment, Tom1L1 was
located at both the plasma membrane and in punctate
structures beneath the membrane (Figure 3A). After
20–30min, Tom1L1 became enriched in punctate structures
characteristic of endosomes. Tom1L1 exhibited cytosolic
distribution after prolonged treatment (180min) with EGF.
The structures marked by Tom1L1 during the 20–30min
period were also enriched for the early endosomal
marker, EEA1, but segregated away from the structures
marked by the late endosomal and lysosomal marker,
LAMP1 (Figure 3C). These results suggest that EGF
stimulated the recruitment of cytosolic Tom1L1 onto the
plasma membrane whereupon Tom1L1 was Tyr-phosphory-
lated and complexed with EGFR. The membrane pool of
Tom1L1 then redistributed with EGFR into the early endo-
some. As Tom1L1 was no longer phosphorylated after 20min
of stimulation, the retention of the membrane pool of Tom1L1
on the early endosome during the process of EGFR endocy-
tosis is probably not dependent on its Tyr-phosphorylation.
We speculate that this is likely mediated by its interaction
with other endosomal proteins such as Hrs and/or TSG101,
which are known to interact with Tom1L1 (Puertollano,
2005).
Mutant forms of Tom1L1 defective in
Tyr-phosphorylation and/or interaction with
Grb2 inhibit endocytosis of EGFR
The functional signiﬁcance of EGF-stimulated Tyr-phosphor-
ylation of Tom1L1 and its interaction with EGFR was inves-
tigated. First, the effect of various mutants of Tom1L1 was
examined. Cells were incubated with Texas Red-EGF on ice
for 60min to allow binding to surface EGFR. After washing,
cells were incubated at 371C for 3h to allow its internaliza-
tion and delivery to the lysosome for degradation. To
visualize surface-bound Texas Red-EGF, cells were ﬁxed im-
mediately after washing. Under this condition, A431 cells and
A431 cells expressing HA–Tom1L1, Tom1L1–SH3, Tom1L1/
Y460F all exhibited comparable levels of binding of Texas
Red-EGF (Figure 4A, left panels), which has a characteristic
surface appearance highlighted by the labelling of cell bound-
aries. After incubation at 371C for 3h, the majority of Texas
Red-EGF was essentially degraded in A431 cells as well as in
A431 cells expressing HA–Tom1L1 and Tom1L1–SH3 with
trace amounts on the plasma membrane and in intracellular
punctates (Figure 4A, right panels). However, in cells expres-
sing Tom1L1/Y460F, a signiﬁcant amount of Texas Red-EGF
remained detectable on the plasma membrane and intracel-
lular punctate structures. Similar blockage of endocytosis and
degradation of Texas Red-EGF was seen in cells expressing
Tom1L1/Y392F and Tom1L1/Y460F–SH3 (data not shown).
We next examined EGFR degradation induced by EGF. Cells
were incubated with EGF for 0min or 3h at 371C and total
cell lysates were used for immunoblot (Figure 4B).
Densitometric analysis of the immunoblots was performed
(Figure 4C). A comparison on the amount of EGFR in the
control A431 cells at 0 versus 3h (Figure 4B, lane 1, ﬁrst and
second panel) indicated that about 80% of EGFR was
degraded after 3h at 371C, as only about 20% of EGFR was
detected. In cells stably expressing HA-tagged Tom1L1 (lane
2) and Tom1L1–SH3 (lane 3), EGFR degradation was slightly
but reproducibly enhanced because around 15% EGFR was
detected. In cells expressing HA-tagged Tom1L1/Y460F (lane
4), Tom1L1/Y460F–SH3 (lane 5) and Tom1L1/Y392F (lane
6), EGFR degradation was signiﬁcantly impaired as about
50% of EGFR remained. These results suggest that Tom1L1/
Y460F, Tom1L1/Y460F–SH3 and Tom1L1/Y392F, which are
no longer able to associate with activated EGFR because of
defects in Tyr-phosphorylation and/or interaction with Grb2,
signiﬁcantly blocked internalization/degradation of Texas
Red-EGF and inhibited EGF-stimulated degradation of EGFR
(Figure 4B and C).
To directly deﬁne a function for Tom1L1 in the internaliza-
tion of EGFR, we monitored by immunoﬂuorescence micro-
scopy, the distribution of activated EGFR using an antibody
(anti-pEGFR), which preferentially recognizes Tyr-phos-
phorylated EGFR (this antibody also recognizes unpho-
sphorylated EGFR with less efﬁciency, Supplementary
Figure S2, second panel). EGFR was initially detected on
the cell surface in both A431 cells and cells expressing
various forms of Tom1L1 (Figure 5A, left panels). After
stimulation with EGF for 20min, EGFR was mainly distrib-
uted in intracellular vesicular structures with some being
detected on the surface in A431 cells (Figure 5A, panel d).
Similarly, EGFR was predominantly detected in the intracel-
lular vesicular structures in cells expressing Tom1L1 (panel h)
or Tom1L1–SH3 (panel l) with noticeably less amounts
Tom1L1 as an adaptor for EGFR endocytosis
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nently detected on the cell surface in cells expressing
Tom1L1/Y460F (panel p) or cells expressing Tom1L1/Y392F
or Tom1L1/Y460F–SH3 cells (data not shown). These results
suggest that Tom1L1/Y460F, Tom1L1/Y392F and Tom1L1/
Y460F–SH3 inhibited EGFR endocytosis. We next monitored
the internalization of surface-biotinylated EGFR in response
to EGF (Figure 5B) followed by quantitative analysis by
densitometry (Figure 5C), as biotinylation is widely used to
selectively mark surface-exposed proteins including EGFR
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Figure 3 EGF stimulates recruitment of Tom1L1 from the cytoplasm to the plasma membrane followed by redistribution to the endosome.
(A) A431 cells treated with EGF (100ng/ml) for the indicated period of time were analysed by immunoﬂuorescence microscopy using anti-
pTom1L1 antibody. Bar, 10mM. (B) A431 cells treated with EGF (100ng/ml) for 2min were analysed by indirect immunoﬂuorescence
microscopy using anti-pTom1L1 antibody and antibodies against the indicated proteins. Bar, 10mM. (C) A431 cells treated with EGF (100ng/ml)
for 30min were analysed by immunoﬂuorescence microscopy using anti-pTom1L1 and antibodies against the indicated proteins. Bar, 10mM.
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(Choi et al, 2004; Elia, 2008). Cells were surface biotinylated
with a cleavable biotin to biotinylate surface proteins. After
washing, biotinylated EGFR was stimulated with EGF to
induce internalization at 371C for various periods of time.
Cells were then quickly chilled on ice to stop additional
endocytosis and then treated with membrane-impermeable
reducing agents to remove biotin attached to surface-exposed
EGFR in a process referred to as surface stripping. The biotin
attached to EGFR molecules that have already been inter-
nalized is resistant to surface stripping. Biotinylated EGFR
can be retrieved by straptavidine beads for detection by
immunoblot. In this assay, the amount of biotinylated EGFR
that is resistant to surface stripping serves as a quantitative
and direct measure of the amount of internalized EGFR.
Using this approach, essentially all surface-biotinylated
EGFR was sensitive to the surface stripping at the beginning
of EGF stimulation (lane 2). Within 2min of stimulation,
about 60% of EGFR had become resistant to surface stripping
(lane 3), suggesting that the majority of EGFR had been
sequestered into clathrin-coated vesicles that were no longer
accessible to externally applied reducing agents. The amount
of internalized EGFR increased gradually over 5–20min
(lanes 4–5) with 495% of biotinylated EGFR becoming
resistant to surface stripping after 20min (lane 6). Similar
kinetics of endocytosis was observed in cells expressing
Tom1L1 or Tom1L1–SH3. In cells expressing Tom1L1/
Y460F, the majority (about 80%) of EGFR remained sensitive
to surface stripping after 2min of stimulation because only
around 20% of EGFR became resistant to the stripping. The
amount of internalized EGFR increased gradually over
5–20min period with about 70% of EGFR being internalized
after 20min of stimulation. Similar delay of EGFR endocytosis
was observed in cells expressing Tom1L1/Y392F or Tom1L1/
Y460F–SH3 (Figure 5C). Hence, the most dramatic inhibition
of EGFR internalization occurred at 2min with 60% being
internalized in control cells compared with 20% being inter-
nalized in cells expressing Tom1L1/Y460F, Tom1L1/Y392F
or Tom1L1/Y460F–SH3. Tom1L1 may thus have a crucial
function in the early events of EGFR endocytosis when
activated EGFR is being sorted and sequestered into
clathrin-coated pits/vesicles.
siRNA-mediated knockdown of Tom1L1 inhibits
endocytosis of EGFR
To verify a function for Tom1L1 in endocytosis by an inde-
pendent approach, we used siRNA-mediated knockdown to
reduce the expression of endogenous Tom1L1 and to examine
the consequence on EGFR degradation (Figure 6A and B) and
endocytosis (Figure 6C and D). After stimulation with EGF for
3h, about 80% of EGFR was degraded in cells transfec-
ted with either non-targeting siRNA or cells treated with
siRNA-targeting GAPDH (Figure 6A, lanes 1–2). However,
EGFR degradation was compromised in cells transfected
with siRNA-targeting Tom1L1 with only 50% of EGFR
being degraded (Figure 6A, lane 3). The endocytosis of
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Figure 4 Tom1L1 mutants defective in Tyr-phosphorylation and/or interaction with Grb2 delay degradation of EGF and EGFR. (A) A431 cells
or A431 cells expressing HA–Tom1L1 or its mutants as indicated were incubated with Texas Red-EGF (20ng/ml) on ice for 60min. After
washing, the cells were incubated at 371C for 0h (left panels) or 3h (right panels). Cells were analysed by immunoﬂuorescence microscopy to
detect Tom1L1 and to visualize Texas Red-EGF. Bar, 10mM. (B) Cells as indicated were incubated with EGF (100ng/ml) at 371C for 0 or 3h. Cell
lysates were analysed by immunoblot to detect EGFR at 0h (upper panel) or 3h (the second panel), Tom1L1 at 3h (the third panel, in which
both endogenous Tom1L1, the lower band, and HA-Tom1L1, the upper band, were detected), and b-tubulin at 3h (bottom panel). (C) The
results from three independent experiments exampled in (B) were quantiﬁed by densitometric analysis for EGFR levels at 0 and 3h. After being
normalized against the level of b-tubulin, the averages of the percentage of EGFR detected at 3h (relative to the EGFR level at 0h being set as
100%) are presented as mean±s.d.
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In cells transfected with the non-targeting siRNA or siRNA
for GAPDH, about 60% of EGFR was internalized after EGF
stimulation for 2min (lane 3). However, the majority of EGFR
was not internalized in cells transfected with Tom1L1 siRNA
as only 20% of the biotinylated EGFR was protected from the
surface stripping. The kinetics of EGFR internalization in cells
treated with Tom1L1 siRNA (Figure 6D) was similar to that
observed in cells expressing dominant-negative mutants of
Tom1L1 (Figure 5C). To verify that the observed defect in
EGFR endocytosis is due to the silencing of Tom1L1 by its
siRNA, we examined the ability of RNAi-resistant Tom1L1
cDNA to restore endocytosis of EGFR. Signiﬁcantly, the defect
of EGFR endocytosis in Tom1L1 siRNA-transfected cells could
be rescued by siRNA-resistant cDNA encoding mouse Tom1L1
(Figure 6E, second panel, lane 3; Figure 6F), but not by cDNA
encoding human Tom1 (Figure 6E, second panel, lane 4;
Figure 6F). The function of Tom1L1 in EGFR endocytosis is
speciﬁc as knockdown of Tom1 or Tom1L2 did not affect EGF-
stimulated endocytosis of EGFR (Figure 6G and H). These
results suggest that endogenous Tom1L1 has an important
and speciﬁc function in EGFR endocytosis.
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Figure 5 Tom1L1 mutants defective in Tyr-phosphorylation and/or interaction with Grb2 delay EGF-induced endocytosis of EGFR. (A) A431
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panels) and analysed by immunoﬂuorescence microscopy to detect Tom1L1 and EGFR. Bar, 10mM. (B) A431 cells expressing indicated proteins
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clathrin-interacting motif
Tom1 contains a well-deﬁned clathrin-binding motif in the
C-terminal region (Yamakami et al, 2003; Seet and Hong,
2005) and Tom1L1 and Tom1L2 are also able to bind clathrin
through their C-terminal tails (Katoh et al, 2006). We
attempted to deﬁne a region of Tom1L1 necessary for inter-
action with clathrin as assessed by GST-pull down experi-
ments using various fusion proteins of Tom1L1 (depicted
schematically in Figure 7A) to retrieve clathrin heavy chain
(CHC) from A431 cell cytosol. GST–Tom1L1(316–476) was
able to retrieve CHC (Figure 7B, lane 3). Truncation experi-
ments revealed that the region between residues 316 and 419
was not important for interaction with CHC (7B, lanes 4–7),
suggesting that the C-terminal 57-residue tail (residues 420–
476) is sufﬁcient for interaction with CHC. This region does
not contain a conventional clathrin-binding motif for
N-terminal region of CHC (Dell’Angelica, 2001; Drake and
Traub, 2001; Miele et al, 2004). Analysis of another set of
C-terminally truncated deletion mutants of GST–Tom1L1
revealed that the region encompassing residues 286–450
was able to interact with CHC (Figure 7C, lane 4), whereas
the fragment consisting of residues 286–441 was defective in
interaction with CHC (Figure 7C, lane 3), suggesting that the
residues 441–450 are necessary for CHC interaction. These
observations narrowed the critical clathrin-binding residues
down to a 31-residue region comprising residues 420–450
(Supplementary Figure S5A, blue box). Within this 31-residue
region are the LPPLP motif predicted in interaction with SH3
domain and YEVM motif predicted in interaction with p85
subunit of PI3K. To deﬁne residues within this region im-
portant for interaction with clathrin, we have focused on
other residues in this region while keeping these motifs
intact. We have chosen three stretches (Supplementary
Figure S5A, purple boxes) with four residues each for further
examination. Using GST–Tom1L1 (286–476) as the frame-
work, we performed site-directed mutagenesis in these three
stretches by changing all four residues of each stretch into Ala
and examining the consequence on interaction with clathrin.
This analysis led to the identiﬁcation of the
447FDPL
450 motif
being important for CHC interaction (Figure 7D). The region
centred at FDPL motif does not share sequence homology
with consensus clathrin-binding boxes, suggesting that this is
likely part of a novel clathrin-binding motif. Ala-scanning
mutagenesis of each residue of the VMEFDPL stretch suggests
that changing individual residue did not affect the interaction
with clathrin (Supplementary Figure 5B), which is in marked
contrast with canonical clathrin-binding motif such as that of
Ack1 in that changing each residue of the clathrin box
abolished interaction with clathrin (Teo et al, 2001). These
results support the notion that FDPL is part of a novel
clathrin-interacting module. To deﬁne the region of CHC
that is involved in interaction with Tom1L1, we have pro-
duced six Myc-tagged fragments corresponding to different
overlapping regions of CHC using the in vitro TNT transcrip-
tion and translation system (Figure 7E). The translation
reactions were then incubated with immobilized GST–
Tom1L1(285–476) and GST–Tom1L1(285–476) FDPL450
AAAA to identify the CHC region capable of interacting
with Tom1L1 in a
447FDPL
450-dependent manner. The
in vitro translated Myc-tagged fragments encompassing resi-
dues 1–363 (Figure 7E, lane 1), residues 327–542 (lane 4),
residues 532–834 (lane 7), residues 824–1129 (lane 10),
residues 1121–1335 (lane 13) and residues 1325–1675 (lane
16) were all detected by anti-Myc antibodies. When these
translated reactions were incubated with immobilized GST-
fusion proteins, only the C-terminal fragment (residues 1325–
1675) was efﬁciently retained by GST–Tom1L1(285–476)
(lane 18), but not by FDPL450AAAA mutant (lane 17).
The results suggest that the C-terminal region of CHC is
able to interact with Tom1L1. As CHC fragment consisting
residues 1325–1675 puriﬁed by immunoprecipitation was
also able to interact with immobilized GST–Tom1L1
(285–476) (Figure 7F), the interaction of Tom1L1 with the
C-terminal region of CHC is likely to be direct. Consistent
with the fact that canonical clathrin box interacts with
N-terminal region of clathrin, GST–Ack1(564–582) (Teo
et al, 2001) was able to pull down myc-clathrin(1–363), but
not myc-clathrin(1325–1675) (Figure 7G). Under the same
conditions, GST–Tom1L1(438–457) was able to pull down
myc-clathrin(1325–1675), but not myc-clathrin(1–363).
These results suggest that the 20-residue region (438–457)
(green box, Supplementary Figure 5A) of Tom1L1, but not
canonical clathrin box of Ack1, is sufﬁcient to interact with
the C-terminal region of clathrin.
To establish that Tom1L1 interaction with clathrin is im-
portant for EGFR endocytosis, we performed rescue experi-
ments in A431 cells in which Tom1L1 was knocked down.
RNAi-resistant mouse cDNAs encoding wild type or various
mutants of mouse Tom1L1 were introduced into the siRNA-
treated A431 cells. Internalization of surface-biotinylated
EGFR was assessed at 2min on stimulation with EGF.
As shown in Figure 7H and quantiﬁed in Figure 7I, Tom1L1
siRNA-treated A431 cells internalized about 20–30%
EGFR (second panel, lane 2) compared with 50–60% of
EGFR being internalized in control cells (lane 1). When
mouse Tom1L1 was introduced by retroviral infection into
the knockdown cells, internalization of EGFR was rescued
signiﬁcantly to about 40–50% (lane 3). When the clathrin-
binding
446FDPL
449 motif was mutated in mouse Tom1L1, the
mutant failed to rescue the endocytosis of EGFR in the
knockdown cells (lane 4), whereas another mutant altering
DLQP region (which is not involved in CHC interaction,
Figure 7D, lane 5) was still able to rescue the endocytosis
(Figure 7H, lane 5). Furthermore, mouse Tom1L1 mutants
equivalent to human Tom1L1/Y460F (lane 6) or Tom1L1/
Y392F (lane 7) also failed to rescue the defect of EGFR
endocytosis in the knockdown cells. These results suggest
that interactions with clathrin and EGFR are both important
for Tom1L1 to mediate endocytosis of EGFR in response to
EGF stimulation.
Discussion
Although AP-2 adaptor complex is the major adaptor impor-
tant for endocytosis of diverse surface proteins, several
independent lines of evidence suggest that endocytosis of
EGFR is primarily mediated by an AP-2-independent, but
clathrin-dependent process (Nesterov et al, 1999; Conner
and Schmid, 2003; Motley et al, 2003; Traub, 2003;
Lakadamyali et al, 2006). Consistent with these studies,
knockdown of CHC inhibited endocytosis of EGFR to levels
comparable to those when Tom1L1 was knocked down,
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of EGFR, although it potently inhibited endocytosis of TfR
(Supplementary Figure S6). These studies suggest that addi-
tional or alterative adaptor (s) is responsible for bridging
EGFR with the endocytic machinery. Our studies suggest that
Tom1L1 is a regulated adaptor for EGFR endocytosis. First,
Tom1L1 is transiently associated with activated EGFR during
the very early events of EGF stimulation. This interaction
depends on transient Tyr-phosphorylation of Tom1L1 through
EGFR-activated Src kinases and is likely to be mediated by
C
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a novel clathrin-interacting motif that is not only essential for
interaction with clathrin, but also important for exogenous
Tom1L1 to functionally rescue endocytosis of EGFR in
Tom1L1 knockdown cells. Third, on EGFR activation,
Tom1L1 was rapidly recruited from the cytoplasm to the
plasma membrane and redistributed with EGFR into the
early endosome. In support of biochemical and morphologi-
cal results, Tom1L1 is important for EGFR endocytosis. First,
the extent of EGFR endocytosis correlates well with Tyr-
phosphorylation of EGFR and Tom1L1, and interaction of
Tom1L1 with EGFR when cells were treated with different
concentrations of EGF (Supplementary Figure S7A). Second,
mutants of Tom1L1 incapable of interaction with EGFR
because of a defect in Tyr-phosphorylation (Tom1L1/Y460F)
or interaction with Grb2 (Tom1L/Y392F) behaved similar to
dominant-negative mutants. Third, RNAi-mediated knock-
down of endogenous Tom1L1, but not Tom1 or Tom1L2,
inhibited EGFR endocytosis. Importantly, exogenous
Tom1L1, but not Tom1, was able to signiﬁcantly rescue the
endocytosis defect of EGFR in Tom1L1 knockdown cells. This
system also allowed us to show that the clathrin-interacting
motif and the motifs responsible for interaction with acti-
vated EGFR are important for exogenous Tom1L1 to rescue
the endocytosis of EGFR. This correlation between Tom1L1
and EGFR interaction and a crucial function for Tom1L1 in
endocytosis provides mechanistic insights into the function of
Tom1L1 as a regulated adaptor mediating endocytosis of
EGFR. Consistent with a function of Src, Grb2 and Shc in
mediating interaction of Tyr-phosphorylated Tom1L1 with
activated EGFR, treatment of the Src kinase inhibitor PP1 or
knockdown of Grb2 or Shc signiﬁcantly inhibited endocytosis
of EGFR (Wilde et al, 1999; Jiang et al, 2003; Huang and
Sorkin, 2005) (Supplementary Figure S7B and C), which is
further supported by the robust inhibition of Tom1L1–EGFR
interaction (Figure 2D) and EGFR endocytosis (Supple-
mentary Figure S7C) when both Grb2 and Shc were knocked
down. The reported association of Grb2 with clathrin-
coated buds/vesicles responsible for EGFR endocytosis
(Johannessen et al, 2006) and the interaction between Grb2
SH3 domain and N-terminal pro-rich region of Shc (Khanday
et al, 2006) also supports our hypothesis. The fact that GGAs,
other VHS domain proteins, act as adaptors in mediating
sorting of M6PR at the TGN (Bonifacino, 2004) is also
consistent with this conclusion. These results allow us to
propose a working model for Tom1L1 to act as a regulated
adaptor in mediating EGF-stimulated endocytosis of EGFR
(Figure 7J).
It is noteworthy that, in response to EGF stimulation,
Tom1L1 is initially associated with the plasma membrane
and subsequently enriched in the early endosome with EGFR
during endocytosis. The latter occurs 20–30min after EGF
stimulation, and by then Y460 of Tom1L1 is already depho-
sphorylated. It thus seems likely that the early endosome-
associated Tom1L1 may engage in interactions with other
proteins such as Hrs and TSG101; and this endosomal
Tom1L1 may participate in the efﬁcient segregation of EGFR
in the maturing endosome to form the MVB (the late endo-
some) for subsequent delivery to the lysosome (Futter et al,
1996; Puertollano, 2005; Lakadamyali et al, 2006; Razi and
Futter, 2006). In this way, phosphotyrosine-mediated recruit-
ment of Tom1L1 to activated EGFR on the plasma membrane
not only triggers internalization, but may also prime Tom1L1
to stay onto the early endosome for subsequent interaction
with the sorting machinery for efﬁcient segregation of EGFR
into the MVB. Further experiments are needed to examine
this hypothesis.
One interesting issue to be resolved by future experiments
is the relationship between Tom1L1 and c-Cbl during EGFR
endocytosis. c-Cbl is known to be an E3-ubiquitinating
enzyme for attaching multiple mono-ubiquitin moieties to
the cytoplasmic domain of EGFR, a modiﬁcation involved in
endocytosis and subsequent sorting of internalized receptor
to MVB (Rubin et al, 2005; Citri and Yarden, 2006). Consistent
with a function of c-Cbl in endocytosis, knockdown of Cbl
also inhibited endocytosis of EGFR (Supplementary
Figure S6). Although c-Cbl is important in mediating EGFR
endocytosis by mono-ubiquitinating multiple sites in
the cytoplasmic tail of EGFR, RNAi of individual ubiquitin-
interacting proteins such as EPS15, ESP15R or Epsin has little
Figure 6 Knockdown of Tom1L1 delays EGF-induced degradation and endocytosis of EGFR. (A) A431 cells transfected with control non-
targeting siRNA (lane 1), GAPDH-targeting siRNA (lane 2) or Tom1L1-targeting siRNA (lane 3) were incubated with EGF (100ng/ml) at 371C
for 0 or 3h. Cell lysates were analysed by immunoblot to detect EGFR at 0h (upper panel) or 3h (second panel), Tom1L1 at 3h (third panel)
and GAPDH at 3h (bottom panel). (B) The results from three independent experiments as exampled in (A) were quantiﬁed by densitometric
analysis for EGFR levels at 0 and 3h. Each column represents the percentage of EGFR detected at 3h relative to 0h, normalized against
b-tubulin (not shown). The mean±s.d. are shown. (C) A431 cells transfected with control non-targeting siRNA (upper panel), GAPDH-
targeting siRNA (middle panel) or Tom1L1-targeting siRNA (bottom panel) were surface biotinylated with sulfo-NHS-SS-biotin. After
incubation with EGF (100ng/ml) at 371C for the indicated period of time, surface-exposed biotin was removed by stripping in reducing
buffer. Biotinylated proteins were recovered and analysed by immunoblot to detect EGFR. (D) The results from three independent experiments
exampled in (C) were quantiﬁed by densitometric analysis. Each signal is normalized against the level of b-tubulin detected at each time point
(not shown). Values are expressed as percentage of signal at each time point relative to signal detected at 0min (100%). The mean±s.d. are
shown. (E) A431 cells transfected with indicated siRNAwere then infected with retrovirus expressing RNAi-resistant mouse Tom1L1 (lane 3) or
human Tom1 (lane 4) to examine the ability to restore EGFR internalization. The amount of biotinylated EGFR at 0min is shown in the ﬁrst
panel, whereas the amount of biotinylated EGFR endocytosed after 2min is shown in the second panel. The cell lysates were also analysed as
indicated (the bottom panels). (F) The results from three independent experiments exampled in (E) were quantiﬁed by densitometric analysis.
Each signal is normalized against the level of b-tubulin detected at 2min. Values are expressed as ratio of signal at 2min to that detected at
0min (100%). The mean±s.d. are shown. (G) A431 cells were transfected with control non-targeting siRNA or siRNA-targeting Tom1, Tom1L1
or Tom1L2 as indicated. Starved cells were surface biotinylated. Cells were stimulated with EGF (100ng/ml) at 371C for 2min to induce
endocytosis of EGFR. Biotinylated and endocytosed EGFR at 2min of EGF stimulation was recovered and then analysed by immunoblot
(second panel). The total amount of biotinylated EGFR at 0min (ﬁrst panel) was also detected. Starting cell extracts were also analysed as
loading controls (the bottom 4 panels). (H) The amount of total biotinylated EGFR at 0min as well as those endocytosed after 2min were
quantiﬁed by densitometric analysis and normalized against the levels of b-tubulin. The average of three independent experiments expressed
as the percentage of the amount of endocytosed receptor at 2min relative to the total amount at 0min is shown as mean±s.d.
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ubiquitinated for a prolonged period of time from 2min
onwards until 120min after EGF stimulation (Shtiegman
et al, 2007; Stern et al, 2007), whereas Tom1L1 is only
transiently associated with Tyr-phosphorylated EGFR
during 2–10min period of EGF stimulation, interaction of
Tom1L1 with EGFR correlated with Tyr-phosphorylation
rather than ubiquitination of EGFR (Shtiegman et al,2 0 0 7 ;
Stern et al, 2007). On this note, Tom1L1 may act indepen-
dently of c-Cbl for interaction with EGFR. A recent study has
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The EMBO Journal VOL 28 | NO 22 | 2009 &2009 European Molecular Biology Organization 3496Figure 7 Tom1L1 contains a novel clathrin-binding motif important for endocytosis of EGFR. (A) Schematic diagram of various C-terminal
fragments of Tom1L1 expressed as GST-fusion proteins and their ability to interact with the CHC. (B–D) Various C-terminal fragments of
Tom1L1 in the form of GST-fusion proteins were immobilized onto glutathione-sepharose beads. Cytosol derived from A431 cells was incubated
with these beads and the proteins retained by the beads were resolved by SDS–PAGE followed by immunoblot to detect CHC (upper panel). GST
and GST-fusion proteins were stained by Coomassie blue (bottom panel). Aliquots of cytosol were also analysed as loading control. (E) Various
fragments of CHC in the form of Myc-tagged polypeptides as indicated (the fragments of expected size were indicated by red arrow heads) were
expressed in the TNTsystem. A measure of 50ml of each of the translation reactions were incubated with immobilized GST–Tom1L1(286–476)
FDPL450AAAA or GST–Tom1L1(286–476), respectively, and the proteins retained by the beads were resolved by SDS–PAGE followed by
immunoblot to detect the Myc-tagged fragments. Only C-terminal fragment (residues 1325–1675) was retained by GST–Tom1L1 (286–476), but
not by the mutant FDPL450AAAA. (F) Myc-tagged C-terminal fragment (residues 1325–1675) of CHC was expressed in the TNT system and
then puriﬁed by immunoprecipitation. The eluted proteins were incubated with immobilized GST-fusion proteins and the retained proteins
were analysed by immunoblot to detect the Myc-tagged fragment of CHC. GST–Tom1L1(286–476), but not GST–Tom1L1(286–
476)FPDL450AAAA was able to retain the CHC fragment. (G) Myc-tagged N-terminal (1–363) or C-terminal (1325–1676) domain of CHC
expressed in the TNT system was incubated with immobilized GST, GST–Tom1L1(438–457) or GST–Ack1(564–582), respectively, and the
proteins retained by the beads were resolved by SDS–PAGE followed by immunoblot to detect the Myc-tagged fragments of CHC. (H) A431
cells were transfected with control non-targeting siRNA (lane 1) or Tom1L1-targeting siRNA (other lanes). The cells were either not infected
(lanes 1–2) or infected with retrovirus to express RNAi-resistant mouse Tom1L1 (lane 3) or the indicated mutants (lanes 4–7) to determine their
ability to rescue EGFR internalization. The amount of biotinylated EGFR at 0min is shown in the ﬁrst panel, whereas the amount of
biotinylated EGFR endocytosed after 2min is shown in the second panel. As shown, the reduced EGFR endocytosis caused by RNAi of Tom1L1
(lane 2) can be restored signiﬁcantly by exogenous mouse Tom1L1 (lane 3), mouse Tom1L1/DLQP437AAAA (lane 5), but not mouse Tom1L1/
FDPL449AAA defective in clathrin-binding (lane 4), mouse Tom1L1/Y457F (which is equivalent to human Tom1L1–Y460F defective in Tyr-
phosphorylation) (lane 6) or Tom1L1/Y392F (which is defective in interaction with Grb2) (lane 7). (I) The results from three independent
experiments were quantiﬁed. Each signal is normalized against the level of b-tubulin detected at 2min. Values are expressed as percentage of
signal at 2min relative to that detected at 0min (100%). The mean±s.d. are shown. (J) A working model for Tom1L1 to act as a regulated
adaptor mediating EGF-stimulated endocytosis of EGFR. On EGF stimulation, EGFR dimerizes, leading to the activation of its cytoplasmic
kinase domain and Tyr-phosphorylation at multiple sites, which then serve as docking sites for various signalling proteins such as Shc/Grb2
and Src kinases; activated Src family kinases phosphorylate Y460 of Tom1L1, causing a transient interaction of pTom1L1 with the activated
EGFR through Grb2/Shc. By interacting with clathrin, pTom1L1 can bring endocytic machinery to mediate the segregation of activated
EGFR into clathrin-coated structures for endocytosis. Other proteins such as dynamin and c-Cbl may be independently recruited to complete
the endocytosis. After endocytosis, pTom1L1 becomes dephosphorylated and the dephosphorylated Tom1L1 is retained on the early
endosome probably through its interaction with Hrs and TSG101 (Puertollano, 2005), in which it may potentially facilitate the sorting of
EGFR into the MVB.
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tosed normally, but severely impaired in degradation by the
lysosome because of an arrest in the early endosome. These
results suggest that c-Cbl-mediated ubiquitination of EGFR
may primarily regulate endosomal sorting to the MVB/
lysosome and another mechanism may account for c-Cbl
participation in endocytosis (Huang et al, 2006). Dual
recognition of EGFR by Tom1L1 and c-Cbl is likely to be
important in mediating overlapping aspects of EGFR trafﬁc in
which Tom1L1 acts primarily in endocytosis, whereas c-Cbl-
mediated ubiquitination acts mainly in the endosomal sorting
of EGFR (Clague and Urbe, 2006; Huang et al, 2006; Su et al,
2007).
It was reported that, in HeLa cells, there exist two different
trafﬁcking routes for EGFR internalization depending on the
dose of EGF (Sigismund et al, 2005). At low EGF doses, EGFR
endocytosis is mediated by clathrin-dependent pathway,
whereas high doses of EGF trigger EGFR internalization
through both clathrin-dependent and clathrin-independent
pathways. In our study, we have observed that endocytosis
of EGFR in A431 cells correlates well with the dose-dependent
activation of EGFR, Tyr-phosphorylation of Tom1L1 and
interaction of Tom1L1 with EGFR in that optimal endocytosis
of EGFR was observed at 15–20ng/ml of EGF or higher
(Supplementary Figure S7A, lanes 4–7). Lower dose of EGF
stimulated less endocytosis (Supplementary Figure S7A,
lanes 1–3), correlating with partial Tyr-phosphorylation of
EGFR and Tom1L1, and less interaction of Tom1L1 with
EGFR. The endocytosis we were measuring thus correla-
tes well with activation of EGFR, Tyr-phosphorylation of
Tom1L1 and interaction of Tyr-phosphorylated Tom1L1 with
activated EGFR. Consistently, endocytosis of EGFR induced
by 15ng/ml of EGF was similarly inhibited by Tom1L1/Y460
(Supplementary Figure S8A, second panel) to a level compar-
able to the inhibition observed in cells stimulated with
100ng/ml of EGF (Supplementary Figure S8A, third panel).
In this context, EGFR signalling and trafﬁcking in A431 cells
(Figure 2F, Supplementary Figures 7A and S8A) are some-
how different from those in Hela cells. Two recent studies
showed that endocytosis of EGFR is primarily mediated by
clathrin-dependent pathway, even in the presence of higher
concentrations of EGF (up to 60ng/ml in HeLa cells or
200ng/ml in BSC-1 cells) (Kazazic et al, 2006; Lakadamyali
et al, 2006). Furthermore, Tom1L1/Y460 or Tom1L1 knock-
down also inhibited endocytosis of EGFR triggered by 1.5ng/
ml of EGF in HeLa cells (Supplementary Figure S8B–D). As an
early study indicates that the normal function of AP2 in
EGFR endocytosis may be bypassed by experimental manip-
ulation of incubating cells with EGF ﬁrst at 41C followed by
endocytosis at 371C (Huang et al, 2004), we have also
performed experiments in which both binding and endocy-
tosis were carried out at 371C. The results from these experi-
ments also support a function of Tom1L1 in endocytosis of
EGFR in response to EGF (Supplementary Figure S8C and D).
Consistent with these observations, endocytosis of EGFR
elicited by 100ng/ml of EGF in A431 was potently suppressed
by knockdown of CHC (Supplementary Figure S6). These
results, taken together, suggest that Tom1L1 has a general
function in EGF-stimulated endocytosis of EGFR, regardless
of experimental conditions or cell types.
Materials and methods
These were described as part of the Supplementary data.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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